FDA Recalls Sermorelin Vials Due to Lack of Sterility Assurance
KRS Global Biotechnology is recalling 647 vials of Sermorelin and related peptides because the company cannot ensure the products are sterile.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II. According to the rubric, FDA Class II recalls involving significant injury or property damage reports, or structural defects, are rated as Severe (4). While the specific injury reports are not detailed in the provided text, the lack of sterility assurance for injectable drugs is a significant hazard that aligns with the Severe criteria for Class II recalls.
Plain-English summary
KRS Global Biotechnology, Inc. is recalling 647 vials of Sermorelin, 3 mg/GHRP6, 3 mg/GHRP2, 3 mg/Vial, For SC Use, Vial-Lyophilized, Rx Only. The recall is being conducted because the company lacks assurance of the sterility of these products.
The affected products are distributed nationwide. The recall includes all lots remaining within their expiration dates. The specific NDC number for the recalled product is 3321673816.
Consumers and healthcare providers should stop using these products and contact their healthcare provider for further instructions. The FDA has classified this recall as Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- Sermorelin, 3 mg/GHRP6, 3 mg/GHRP2, 3 mg/Vial, For SC Use, Vial-Lyophilized, Rx Only, KRS Global Biotechnology 791 Park of Commerce Blvd, Boca Raton, FL 33487. NDC 3321673816
- Manufacturer
- KRS Global Biotechnology, Inc
- Category
- Drug — Injectable Peptides
- Hazard
- Affected units
- 647
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots remaining within expiry.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 80 recalled by KRS Global Biotechnology, Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 80 products in this recall →Related recalls
Same manufacturer · KRS Global Biotechnology, Inc
See all →- SevereKRS Global Biotechnology Recalls Lidocaine HCl Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-10-09
- SevereKRS Global Biotechnology Recalls Human Chorionic Gonadotropin Due to Sterility Concerns
FDA (Drugs) · 2019-10-09
- SevereFDA Recalls Phenylephrine IV Bags Due to Sterility Concerns
FDA (Drugs) · 2019-10-09
- ModerateSermorelin and GHRP-2 Lyophilized Vials Recalled Due to Sterility Concerns
FDA (Drugs) · 2019-10-09
- SevereKRS Global Biotechnology Recalls Phenylephrine IV Bags Due to Sterility Concerns
FDA (Drugs) · 2019-10-09
Same hazard · lack of sterility
See all →- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
Similar recalls
- ModerateKRS Global Biotechnology Recalls Sermorelin Vials Due to Labeling Errors
FDA (Drugs) · 2018-01-17
- ModerateKRS Global Biotechnology Recalls Sermorelin Acetate Vials Due to Labeling Errors
FDA (Drugs) · 2018-01-17
- SeverePromise Pharmacy Recalls Sermorelin Injection Due to Sterility Concerns
FDA (Drugs) · 2019-02-20
- ModerateKRS Global Biotechnology Recalls Sermorelin Cartridges Due to Labeling Errors
FDA (Drugs) · 2018-01-17
- SevereSermorelin Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2015-09-23
- SevereDowning Labs Recalls Sermorelin Injection Due to Sterility Concerns
FDA (Drugs) · 2015-11-25